TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM784265

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
OrbiMed Royalty & Credit Opportunities III, LP		01/03/2023	Limited Partnership: DELAWARE

RECEIVING PARTY DATA

Name:	Oyster Point Pharma, Inc.		
Street Address:	202 Carnegie Center Drive, Suite 109		
City:	Princeton		
State/Country:	NEW JERSEY		
Postal Code:	08540		
Entity Type:	Corporation: DELAWARE		

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Serial Number:	88828629	AHVIA
Serial Number:	90581634	DRY EYELAND
Serial Number:	90581636	DRY EYELAND
Serial Number:	88791718	EZVAYA
Serial Number:	88570643	OYSTER POINT
Serial Number:	88570636	OYSTER POINT
Serial Number:	88570647	OYSTER POINT
Serial Number:	88570646	OYSTER POINT
Serial Number:	88872998	TIFIMEO
Serial Number:	88791704	TIRVAYA
Serial Number:	88818863	TYRLIBRIA
Serial Number:	90255562	TYRLIBRIA
Serial Number:	88791721	TYRNAU
Serial Number:	88791700	TYRVAYA
Serial Number:	88873736	TYRVAYA

CORRESPONDENCE DATA

Fax Number: 4156932222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000

Email: crhem@cooley.com

Correspondent Name: Cooley LLP

Address Line 1: 3 Embarcadero Center, 20th Floor
Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	328567-107
NAME OF SUBMITTER:	C. Rhem
SIGNATURE:	/CR/
DATE SIGNED:	02/02/2023

Total Attachments: 4

source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page1.tif source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page2.tif source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page3.tif source=Oyster Point - Termination to Trademark Security Agreement (Execution Version)#page4.tif

TERMINATION TO TRADEMARK SECURITY AGREEMENT

This **TERMINATION TO TRADEMARK SECURITY AGREEMENT** (this "*Termination*"), dated as of January 3, 2023, is executed by OrbiMed Royalty & Credit Opportunities III, LP ("*Administrative Agent*"), with an address at 601 Lexington Avenue, 54th Floor, New York, NY 10022, in favor of Oyster Point Pharma, Inc., a Delaware corporation ("*Grantor*"), with an address at 202 Carnegie Center Drive, Suite 109, Princeton, NJ 08540.

RECITALS

WHEREAS, Grantor and Administrative Agent entered into that certain Security Agreement, dated as of August 5, 2021 (as amended or otherwise modified from time to time, the "Security Agreement");

WHEREAS, in connection with the Security Agreement, Grantor and Administrative Agent entered into that certain Trademark Security Agreement dated as of August 5, 2021 (as amended or otherwise modified from time to time, the "Agreement") pursuant to which Grantor granted to Administrative Agent a security interest in the Trademark Collateral (as defined in the Agreement); and

WHEREAS, Administrative Agent has agreed to terminate and release its security interest in the Trademark Collateral as herein provided.

NOW, THEREFORE, in consideration of the foregoing, Administrative Agent agrees as follows:

- 1. Administrative Agent hereby terminates its security interest in the Trademark Collateral, including without limitation the trademarks listed on *Schedule 1* hereto, which security interest was evidenced by the recordation of the Security Agreement with the United States Patent and Trademark Office on August 16, 2021, in Reel/Frame 7393/0031.
- 2. Administrative Agent may record this Termination with the United States Patent and Trademark Office at the expense of Grantor.
- 3. Administrative Agent hereby irrevocably authorizes Grantor or Grantor's agent to record this Termination with the United States Patent and Trademark Office and any other relevant governmental authority.
- 4. This Termination and the rights and obligations of the parties under this Termination shall be governed by, and construed and interpreted in accordance with, the law of the State of New York.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, Administrative Agent has executed this Termination on the date first written above.

ADMINISTRATIVE AGENT:

ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP

By: OrbiMed ROF III LLC, its general partner By: OrbiMed Advisors LLC, its Managing Member

Title: Member

SCHEDULE 1 to the Termination to Trademark Security Agreement

TRADEMARKS

Trademark Registrations

None.

Trademark Applications

<u>Grantor</u>	<u>Jurisdiction</u>	Application No.	Filing Date	<u>Mark</u>
Oyster Point	United States	Application No.	Filed	AHVIA
Pharma, Inc.		88828629	Mar-10-2020	
Oyster Point	United States	Application No.	Filed	DRY EYELAND
Pharma, Inc.		90581634	Mar-16-2021	
Oyster Point	United States	Application No.	Filed	DRY EYELAND
Pharma, Inc.		90581636	Mar-16-2021	
Oyster Point	United States	Application No.	Filed	EZVAYA
Pharma, Inc.		88791718	Feb-10-2020	
Oyster Point	United States	Application No.	Filed	OYSTER POINT
Pharma, Inc.		88570643	Aug-07-2019	
0 1 1	TI 's 1 Co	A 1' (' NT	T2'1 1	OVICEED DODIE
Oyster Point	United States	Application No.	Filed	OYSTER POINT
Pharma, Inc.		88570636	Aug-07-2019	
Oyster Point	United States	Application No.	Filed	OYSTER POINT &
Pharma, Inc.		88570647	Aug-07-2019	Circle Design
				OYSTER POINT
				P POINT
Oyster Point	United States	Application No.	Filed	OYSTER POINT &
Pharma, Inc.		88570646	Aug-07-2019	Circle Design
				OYSTER POINT
				P POINT
Oyster Point	United States	Application No.	Filed	TIFIMEO
Pharma, Inc.		88872998	Apr-15-2020	
			1	
Oyster Point	United States	Application No.	Filed	TIRVAYA
Pharma, Inc.		88791704	Feb-10-2020	

Schedule 1 Page 1

Oyster Point	United States	Application No.	Filed	TYRLIBRIA
Pharma, Inc.		88818863	Mar-03-2020	
Oyster Point	United States	Application No.	Filed	TYRLIBRIA &
Pharma, Inc.		90255562	Oct-14-2020	Droplet Design
				tyrlibria
				cyi cibi id
Oyster Point	United States	Application No.	Filed	TYRNAU
Pharma, Inc.		88791721	Feb-10-2020	
Oyster Point	United States	Application No.	Filed	TYRVAYA
Pharma, Inc.		88791700	Feb-10-2020	
Oyster Point	United States	Application No.	Filed	TYRVAYA & Droplet
Pharma, Inc.		88873736	Apr-15-2020	Design
				tyrväya

Schedule 1 Page 2

 $\hbox{\tt [[DMS:}5979438v2:12/21/2022--03:07\ PM]]}$

TRADEMARK REEL: 007959 FRAME: 0794

RECORDED: 02/02/2023